COX-2抑制剂治疗良性前列腺增生症引起夜尿症的临床研究

摘要

目的：研究COX-2抑制剂对BPH患者发生夜尿症的疗效.方法：100名患有良性前列腺增生症的患者，平均年龄67岁(59~79岁)，均有夜尿频的症状，并且夜尿次数>2次，均服用α-受体阻滞剂，但夜尿症改善不明显，随机分为两组：一组给予100 mg塞来昔布每晚口服；另一组给予100 mg安慰剂每晚口服，总共持续2周.对比两组服药前后夜尿症改善情况.结果：服用COX-2抑制剂组后，平均夜尿次数由(6.05±2.3)次/晚降为(2.4±1.8)次/晚(P0.05).未发现COX-2抑制剂有明显的不良反应.结论：COX-2抑制剂对患有难治性夜尿症的BPH患者是有效安全的.%　　Objective:To estimate the efficacy of celecoxib, a cyclooxygenase-2 inhibitor, in the treatment of patients with BPH complaining of nocturia. Methods:We assessed 100 BPH patients with symptoms of nocturia at average age 67 (59~79). Among them, the nocturnal frequency should be more than 2, associated with the failure treatment of alpha-blocker. They were randomly divided into two groups:experimental group was received 100 mg of celecoxib at 9 PM for 2 weeks and control group was treated with placebo. Results:The nocturnal frequency was decreased from (6.05±2.3) to (2.4±1.8) (P<0.01) in experimental group with no significant side effects observed. Conclusion:Cyclooxygenase-2 inhibitor is effective in treatment of patients with BPH complaining of refractory nocturia.